Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Arcellx, Inc.
Ryvu Therapeutics SA
Guangzhou Lupeng Pharmaceutical Company LTD.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Biocity Biopharmaceutics Co., Ltd.
Perseus Proteomics Inc.
University of Kansas Medical Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Taiga Biotechnologies, Inc.
Changchun GeneScience Pharmaceutical Co., Ltd.
Guizhou Bailing Group Pharmaceutical Co Ltd
Jasper Therapeutics, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
M.D. Anderson Cancer Center
University College, London
King's College London
Benovus Bio, Inc.
Seoul St. Mary's Hospital
National Cancer Institute (NCI)
Peter MacCallum Cancer Centre, Australia